Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grass pollen sublingual immunotherapy (SLIT) is a therapeutic modality used to treat allergic rhinitis and conjunctivitis induced by grass pollen. It involves the administration of standardized allergen extracts from various grass species (such as Kentucky blue grass, orchard, perennial rye, timothy, and sweet vernal grass) in the form of tablets or drops placed under the tongue. The treatment works by inducing immunotolerance through the modulation of the immune system's response to allergens. Specifically, it promotes the production of protective IgG4 antibodies and reduces the levels of allergen-specific IgE, thereby decreasing the inflammatory response upon natural exposure to grass pollen. Major products in this category include Oralair (developed by Stallergenes Greer) and Grastek/Grazax (developed by ALK-Abelló).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on grass pollen sublingual immunotherapy.